Here we present gene expression data of SV2A, SV2B and SV2C in two human neuroblastoma cell lines after differentiation.<h4>Methods</h4>Human neuroblastoma cell lines SiMa and IMR-32 were treated for seven days with growth supplements (B-27 and N-2), all-trans-retinoic acid (ATRA) or vasoactive intestinal peptide (VIP) and gene expression levels of SV2 and neuronal targets were analyzed.<h4>Results</h4>The two cell lines reacted differently to the treatments, and only one of the three SV2 isoforms was affected at a time. The gene discussed is SV2C; the disease is neuroblastoma.